http://mssm.technologypublisher.comBe the first to know about the latest inventions and technologies available from Mount Sinai School of Medicineen-USWed, 10 Mar 2010 12:18:20 GMTThu, 23 Jul 2009 12:50:40 GMThttp://blogs.law.harvard.edu/tech/rsstechnology@mssm.eduCopyright 2010, Mount Sinai School of Medicinehttp://mssm.technologypublisher.com/technology/3233in preparationThu, 23 Jul 2009 12:50:40 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3233http://mssm.technologypublisher.com/technology/3232In preparationThu, 23 Jul 2009 12:50:39 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3232http://mssm.technologypublisher.com/technology/3231in preparationThu, 23 Jul 2009 12:50:37 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3231http://mssm.technologypublisher.com/technology/3230In preparationThu, 23 Jul 2009 12:50:35 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3230http://mssm.technologypublisher.com/technology/3229In preparationThu, 23 Jul 2009 12:50:35 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3229http://mssm.technologypublisher.com/technology/3228Thu, 23 Jul 2009 12:50:30 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3228http://mssm.technologypublisher.com/technology/3227Background Currently, there are only four FDA-approved drugs available for treatment of influenza virus infection: the neuraminidase inhibitors (Tamiflu by Roche and Relenza by GSK), and the adamantanes (amantadine and rimantadine). For the influenza season 2008-2009, all isolated H3N2 viruses were resistant to the adamantanes while nearly all isolated H1N1 viruses, which have caused the majority of illness this season, were resistant to the neuraminidase inhibitors. The loss of effective therapy for influenza virus infections is significant, and therefore highlights the need for the developme...Thu, 23 Jul 2009 12:50:29 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3227http://mssm.technologypublisher.com/technology/3226 Background Recent genetic studies have documented a pivotal growth-regulatory role played by the Cullin 7 (CUL7) E3 ubiquitin ligase complex containing the Fbw8-substrate-targeting subunit, Skp1, and the ROC1 RING finger protein. Investigators at the Mount Sinai School of Medicine have identified insulin receptor substrate 1 (IRS-1), a critical mediator of the insulin/insulin-like growth factor 1 signaling, as a proteolytic target of the CUL7 E3 ligase in a manner that depends on mammalian target of rapamycin and the p70 S6 kinase activities. Interestingly, while embryonic fibroblasts of Cul7...Thu, 23 Jul 2009 12:50:28 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3226http://mssm.technologypublisher.com/technology/3225Thu, 23 Jul 2009 12:50:27 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3225http://mssm.technologypublisher.com/technology/3224Background The human tumor suppressor p53, referred to as “guardian of the genome”, functions as a transcription factor to regulate expression of a large set of genes that induce cell cycle arrest or apoptosis in response to genotoxic injury. Chemotherapy and radiotherapy, two widely used therapies for cancer patients, are known to cause widespread p53-dependent DNA damage, which triggers potentially lethal pathologies that are generally deemed as unfortunate but unavoidable consequence. Recent pre-clinical studies using a mouse model revealed that p53-induced pathological response to whole-bo...Thu, 23 Jul 2009 12:50:22 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3224http://mssm.technologypublisher.com/technology/3223Thu, 23 Jul 2009 12:50:20 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3223http://mssm.technologypublisher.com/technology/3222In preparationThu, 23 Jul 2009 12:50:15 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3222http://mssm.technologypublisher.com/technology/3221 Background KLF6 is a Kruppel like zinc finger transcription factor which is inactivated by allelic loss and somatic mutation in men with sporadic prostate cancer1. Since the original identification and description by MSSM investigators of the tumor suppressor KLF6 gene and its alternatively spliced “oncogenic” variant KLF6-SV1, these two related genes have been shown by us and others to be inactivated or their expression dysregulated in multiple human cancers, including prostate, ovarian, colorectal, non-small cell lung, gastric, hepatocellular, astrocytic glioma, pancreatic, and head and nec...Thu, 23 Jul 2009 12:50:14 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3221http://mssm.technologypublisher.com/technology/3220In preparationThu, 23 Jul 2009 12:50:13 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3220http://mssm.technologypublisher.com/technology/3219In preparationThu, 23 Jul 2009 12:50:08 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3219http://mssm.technologypublisher.com/technology/3218In preparationThu, 23 Jul 2009 12:50:07 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/3218http://mssm.technologypublisher.com/technology/2714Mon, 08 Jun 2009 10:31:49 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2714http://mssm.technologypublisher.com/technology/2301Wed, 13 May 2009 13:20:33 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2301http://mssm.technologypublisher.com/technology/2060Fri, 10 Apr 2009 13:55:17 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2060http://mssm.technologypublisher.com/technology/2059Fri, 10 Apr 2009 13:55:16 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2059http://mssm.technologypublisher.com/technology/2058Fri, 10 Apr 2009 13:55:16 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2058http://mssm.technologypublisher.com/technology/2057Fri, 10 Apr 2009 13:55:15 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2057http://mssm.technologypublisher.com/technology/2056 AD is one of the most persistent and devastating disorders of old age, often leading to severe memory loss and functional impairment. It is estimated that up to ~ 5 million people in the US currently have AD at an estimated cost to society of greater than $100 billion per year. It is projected that up to 14 million people will be affected by AD by the middle of this century if successful therapies are not developed. At present, the few agents that are approved by the FDA for treatment of AD have demonstrated only modest effects in modifying clinical symptoms, and none has shown a clear eff...Fri, 10 Apr 2009 13:55:14 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2056http://mssm.technologypublisher.com/technology/2055 Hepatocellular carcinoma (HCC), a malignant tumor of the liver, is the third leading cause of cancer-related deaths, the leading cause of death among cirrhotic patients and it accounts for 80-90% of all liver cancers. HCC is notoriously refractory to treatment; when the tumors are small or slow-growing, surgery or liver transplant might be successful if the tumors are diagnosed early. However, because early tumors are difficult to distinguish from pre-neoplastic nodule lesions (such as high-grade dysplastic nodules), early diagnosis is difficult, a situation that has led to the search for mo...Fri, 10 Apr 2009 13:55:13 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2055http://mssm.technologypublisher.com/technology/2054Fri, 10 Apr 2009 13:55:12 GMTtechnology@mssm.eduhttp://mssm.technologypublisher.com/technology/2054